Quris Earns Frost & Sullivan 2022 Europe Know-how Innovation Management Award for AI-Powered Drug Security Prediction

Analysts discovered that the Quris Bio-AI Scientific Prediction Platform enhances drug growth course of agility, shortens discovery timelines, will increase drug security, and improves drug pipeline diversification alternatives

SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ — Frost & Sullivan just lately researched the factitious intelligence (AI)-enabled drug security prediction expertise trade and, based mostly on its findings, acknowledges Quris with the 2022 Europe Know-how Innovation Management Award. The revolutionary Quris Bio-AI Scientific Prediction Platform is the primary AI breakthrough to shut the scientific prediction hole by successfully predicting which drug candidates will work safely in people.

Get entry to extra particulars on the award multi-media web page – https://best-practices.frost.com/quris-technologies/

“Quris AI Chip-on-Chip platform, in contrast to different AI-pharma options specializing in drug discovery, higher signifies which drug candidates will safely work in people. It makes use of AI to foretell a drug’s security, and therefore its potential to succeed, significantly in Part 1 trials, thus avoiding the excessive prices of failed scientific trials for pharmaceutical firms,” stated Supriya Lala Kundu, a Greatest Practices Analysis analyst at Frost & Sullivan.

The corporate’s platform scales to suit the intricacies of scientific prediction, requiring machine studying (ML)  fashions to routinely run an unlimited variety of organic Sufferers-on-a-Chip experiments for AI coaching. Quris’s AI Chip-on-Chip expertise leverages a patented course of to check 1000’s of identified protected and unsafe medicine on 1000’s of miniaturized Sufferers-on-a-Chip making use of an automatic, high-throughput system. Equally, next-generation nano-sensors allow steady response monitoring from every miniaturized organ to those medicine. Furthermore, steady knowledge technology additional trains the ML classification algorithm, making it extremely predictive of scientific security and enabling it to higher discern the toxicity degree of recent drug candidates throughout testing. The revolutionary and ground-breaking platform simulates a pure human physique’s response to novel molecules with out counting on inaccurate animal testing – lowering animal cruelty throughout pre-clinical experimentation as a consequence of its potential to restrict dependence on animal testing.

Ashish Kaul, an trade analyst for Frost & Sullivan, stated, “In contrast to different organ-chip units with restricted potential to run thousands and thousands of experiments, the Quris platform is extremely scalable, enabling large experiments to run cost-effectively and prepare the AI, thereby revolutionizing the pharmaceutical trade. Moreover, the platform can scale as much as 1,000 medicine throughout all therapeutics, notably oncology, uncommon illness, and the blood-brain barrier.”

Quris stands out from rivals based mostly on its dedication to innovation and creativity whereas attaining business success. Along with its drug security prediction pharma providers, Quris additionally has a drug pipeline and supplies personalised medication providers. The corporate has a group of scientists, expertise consultants, medical pioneers, and seasoned administration professionals with a observe document of seamless execution. Its robust mental property portfolio protects its pioneering expertise, including worth relative to its progress potential, thus securing a aggressive benefit. Its first AI-based Fragile-X drug is getting ready for scientific testing later in 2022. Moreover, the corporate has established stem cell facilities worldwide to offer personalised medication providers, additional validating its platform and enabling it to develop by way of strategic partnerships with trade and analysis institutes.

“Recognition by the Frost & Sullivan group additional validates our mission to fully rethink drug growth and resolve the most important drug discovery problem of our period – utilizing AI scientific prediction to take away longstanding limitations for your entire pharma trade. Permitting the environment friendly discovery of recent medicine and the repurposing/personalization of current medicine, Quris will assist pharma firms keep away from the super dangers and prices of failed scientific trials and finish the reliance on ineffective animal testing,” added Quris Founder and CEO Isaac Bentwich.

Annually, Frost & Sullivan presents this award to the corporate that develops a product with revolutionary options and performance that’s gaining speedy acceptance available in the market. The award acknowledges the standard of the answer and the client worth enhancements it permits.

Frost & Sullivan Greatest Practices awards acknowledge firms in varied regional and world markets for demonstrating excellent achievement and superior efficiency in management, technological innovation, customer support, and strategic product growth. Business analysts evaluate market contributors and measure efficiency by way of in-depth interviews, analyses, and in depth secondary analysis to establish finest practices within the trade.

About Frost & Sullivan

For six many years, Frost & Sullivan has been world-renowned in serving to buyers, company leaders, and governments navigate financial adjustments and establish disruptive applied sciences, Mega Traits, new enterprise fashions, and firms to motion, leading to a steady stream of progress alternatives to drive future success. Contact us: Begin the dialogue.


Kristen Moore
E: kirsten.moore@frost.com

About Quris
Quris, the world’s first Bio-AI clinical-prediction platform ensures the protection and efficacy of recent medicine. Revolutionizing the drug growth course of, the corporate is pioneering scientific trials on chips – testing 1000’s of novel drug candidates on tons of of miniaturized “patients-on-a-chip”. Its absolutely automated, self-training AI platform precisely predicts scientific security and efficacy for novel medicine quicker and extra cheaply than ever earlier than – all whereas minimizing animal testing. Twin-headquartered in Boston and Israel and backed by strategic biotech and large knowledge buyers, Quris is led by a confirmed group of AI and medical analysis powerhouses who’re already getting ready its lead discovery for scientific trials. For extra data, go to www.quris.ai. 


Erica Camilo
P: 1.610.639.5644
E: erica@connexacommunications.com

Picture – https://mma.prnewswire.com/media/1887364/Quris_Technologies_Award_Logo.jpg

SOURCE Frost & Sullivan

Supply hyperlink